Collaborative Innovation in Biomedicine

This conference will cover key issues, challenges and best practices for Collaborative Innovation in Biomedicine, including: 

Including Pharmaceutical Company Perspectives on Collaborative Innovation Consortia from:

Merck & Co. | Eli Lilly and Company | GlaxoSmithKline | Pfizer | Johnson & Johnson

Conference Program Advisors:

Dr. William B. Mattes, Director, Toxicology, Critical Path Institute

Dr. Elizabeth G. Walker, Assistant Director, Toxicology, Predictive Safety Testing Consortium, Critical Path Institute

Dr. Jackie Hunter, Senior Vice President, Science Environment Development, GlaxoSmithKline

Dr. Susie M. Stephens, I.T. Manager / Principal Research Scientist, Eli Lilly, Discovery I.T. Department, Eli Lilly and Company

As the pharmaceutical industry moves closer to what has been described as a “Revenue Cliff”, as a number of key patents expire on major drugs, at the same time as the industry confronts the additional challenges of a dramatic decline in pipeline productivity, declining availability of R&D resources, and increased regulatory and business practice pressures, new models for drug discovery and development become critical to the industry’s future. Pre-competitive consortia are becoming an important alternative model for accelerating drug discovery and development, while sharing resources and costs. Current consortia have produced some notable successes and provide a valuable approach for better understanding where the best opportunities for collaboration may exist, what strategies to employ and how to win support for such efforts.

This important program will explore pre-competitive, multiple party, consortia-based collaborations in drug discovery and development, examining key questions and issues, including:

This leading-edge conference will feature key speakers from pharmaceutical companies and non-profit organizations, with first-hand experience in setting up and managing successful consortia, as we explore the most important new models, key issues, challenges and best practices of Collaborative Innovation in Biomedicine.

Case studies of emerging consortia-based models and best practices will be featured from such organizations and consortia as:

We look forward to seeing you at this important conference.

Phillips Kuhl

President, Cambridge Healthtech Institute

Bill Lundberg

Alliance Director and Senior Conference Producer,
Cambridge Healthtech Institute

250 First Avenue, Suite 300

Needham, MA 02494
Phone: 781-972-1346
Email: blundberg@healthtech.com

For information on sponsorships and exhibits, please contact:

Arnie Wolfson

Manager, Business Development,
Cambridge Healthtech Institute

Phone: 781-972-5431
Email: awolfson@healthtech.com